Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-119 pembrolizumab versus physician's choice chemotherapy in metastatic triple-negative breast cancer
2015-001020-27Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2015
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab, capecitabine, eribulin, gemcitabine, vinorelbine in triple-negative breast cancer (TNBC), sponsored by Merck & Co.. Started Aug 2015; status: completed.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2015-001020-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001020-27.